
ERN-EuroBloodNet

Board of Network Meeting 2025















ERN-EuroBloodNet and ENROL Registry

Boosting data driven research and innovative therapies & fostering best practices and access to highly specialized care

Today we are

- 77 Members, APs or patients representatives
- from 53 ERN-EuroBloodNet Healthcare providers
- and 13 EU Member States










ERN-EuroBloodNet and ENROL Registry

Boosting data driven research and innovative therapies & fostering best practices and access to highly specialized care

SUBNETWORKS OF EXPERTISE



ROLES OF PARTICIPANTS

- 41% HCP representatives
- 20% HCP representative's substitutes
- 28% Members of the HCP multidisciplinary team
- 7% Patients representatives
- **4%** Other



ERN-EuroBloodNet results from Monitoring Exercise Reporting year 2024

ERN-EuroBloodNet



90Members from18 Member States




Affiliated Partners
from
6 Member States



53
Patient Organizations
involved



24176 New patients









Non-accredited educational activities

68

Non-accredited educational activities

6 Onsite trainings, 4 Online trainings, 14 Webinars, 48 Videos,

564

Trainees who completed the training

from 4 Onsite trainings, 2 Online trainings and 14 Webinars

43

Countries of origin of trainees



Accredited educational activities

99

Accredited educational activities

4 Onsite trainings, 5 Webinars, 1 Preceptorship,

2061

Trainees who completed the training


from 1 Onsite trainings, 2 Online trainings and 4 Webinars

83

Countries of origin of trainees



Sharing of knowledge and expertise









233

Clinical Trials

Involving at least 2 Members from 2 Member States

1 acknowledging the ERN in clinicaltrials.gov

8 Observational studies

Involving at least 2 Members from 2 Member States & acknowledging the ERN in clinicaltrials.gov

4686

Patients with legal basis

To be uploaded to **ENROL registry** after signature of Data Transfer Agreement

43.82% of Healthcare Providers using ORPHAcodes

9


Peer Reviewed publications

Involving at least 2 Members from 2
Member States
& acknowledging the ERN






- 17 <u>Congresses/conferences/meetings</u> at which the ERN activities and results were presented
- 57 Presentations acknowledging ERN in 17 congresses



- **13485** New visitors to the ERN-EuroBloodNet website
- **2786** Returning visitors
 - 493 Relevant documents downloaded
 - 4 Dissemination webinars
 - **146** Attendees to dissemination webinars





Excellent (90-100%) Very Good (70-89%) Moderate (40-49%) Needs improvement (0-39%)





- 40% REDCap Continuous monitoring on member activities.
 - Reporting all member's coordinated activities
 - ✓ Monitoring criteria fulfilling activities
- 60% Participation to the ERN-EuroBloodNet coordinated activities (Education, Clinical Trials, Observational studies, Publications and Communications, CPGs/CDMT, Presence in ERN-EuroBloodNet annual meetings).



THANK YOU FOR YOUR COLLABORATION!

There are simple ways you can improve your score:

Include the ERN logo and acknowledgement in all the activities coordinated by your HCP.

Find the ERN logo & acknowledgement in our website!

the relevant activities coordinated by your HCP.

In order for the activities reported to be eligible, it is very important to complete the REDCap survey, filling all the required information to be checked against eligibility criteria.

Participate in ERN coordinated activities like Education, Clinical Trials, Observational studies, Publications, Communications, mapping exercises and development of CPGs/CDMT.





ERN-EuroBloodNet actions

(Not presented in today's meeting)





Education Healthcare Professionals



ERN-EuroBloodNet Preceptorships in Aplastic Anemia



Coordination Prof. Carlo Dufour

Preceptorship 1 - Aplastic Anemia in children and adolescents at the IRCCS Istituto Giannina Gaslini, Genoa, Italy.



Preceptorship 2 - Acquired and Inherited Aplastic Anemia in pediatric and adult at the Assistance Publique Hôpitaux de Paris, Hôpital Saint Louis, Paris



Coordination Prof. Jens Panse

Preceptorship 3 - Bone marrow failure syndromes (BMFS) with a focus on aplastic anemia in adults and pediatrics at the University Hospital RWTH Aachen



- 3 webinars in collaboration with ISLH on Rare constitutional coagulation factor bleeding disorders
- Thursday Webinar: 15 webinars held + 4 upcoming
- 1 Topic on Focus on Constitutional Thrombocytopenia (15 webinars)







EHA & ERN-EuroBloodNet Spotlight on Rare Hematological Diseases

2022

Castleman Disease

Prof Eric Oksenhendler France

Prof Kai Hübel Germany

Prof Simone Ferrero Italy

Mark Bower United Kingdom

David Boutboul France

Elena Sabatini Italy

>100 live participants

2024

Hypereosinophilic Syndrome

Prof Massimo Breccia Italy

Prof Florence Roufosse Belgium

>300 live participants

2025

BMF Syndromes

Prof. Régis Peffault de Latour,

France

Prof Achille Iolascon, Italy

Prof Carlo Dufour, Italy

Prof Thierry Leblanc, France

Prof Lidye Da Costa, France

Prof Prof. Roberta Russo, Italy

Prof. Kathleen Freson, Belgium

Dr. Erika Massaccesi, Italy

> 125 live participants







New strategy for patients Education

Integrate Education with Research: Equip patients with evidence-based information, the latest research findings, and cutting-edge tools to support informed decision-making and enhance their care experience.






Trainings for SCD patients at ASCAT



- **ENROL** webinars
 - 3 webinars & 3 videos
- 16 videos on ENROL Registries and PROMs available in 8 languages



How to read a scientific paper in Hemoglobinopathies



- Genomed4all 1st wave
 - 4 webinars & 4 video
- **Genomed4all 2nd wave**
 - 6 webinars & 6 videos



7 webinars focusing Gene Therapy for SCD patient









Patients Actions in collaboration with International stakeholders

Best Practices – CDSTs for patients



- **Developpment of Patient Journey in vWD**
- Developpment of Patient Version of Guidelines in Burkitt Lymphoma



Developpment of the Charter for optimal care transition between paediatric and adult care in sickle cell diseas



Shaping Patient Driven Global strategy in Public Health

 Global survey assessing the perspectives of people living with SCD on how to improve outcomes in SCD

THE LANCET Haematology











ERN-EuroBloodNet Board of Network meeting

SESSION 1: ERN-EuroBloodNet Clinical and Data driven research - 13:15 to 14:30 CEST





"ERN-EuroBloodNet sponsored clinical trials". Pierre Fenaux (AP-HP – Hôpital Saint Louis) & Eduard van Beers (University Medical Center Utrecht)



"Role of ERN Registries in advance research in hematology". Sara Reidel (Vall d'Hebron University Hospital / Vall d'Hebron Research Institute)



"GenoMed4All & SYNTHEMA Al Federated Platforms in hematology. Federico Álvarez (Universidad Politécnica de Madrid)



"Al Federated platform in oncology" Matteo Della Porta (IRCCS Clinical Institute Humanitas di Rozzano)



"Al Federated platform in anemia". María del Mar Mañú Pereira (Vall d'Hebron University Hospital/ Vall d'Hebron Research Institute, Barcelona)



"Radiomics in Sicke Cell Disease". Raffaella Colombatti (Azienda Ospedale – Università Padova)



ERN-EuroBloodNet Board of Network meeting

SESSION 2: Clinical Practice Guidelines (CPGs) & Clinical Decision Support Tools (CDSTs) - 14:45 to 15:35 CEST



"ERN-EuroBloodNet Repository of CPGs/CDSTs". Luca Malcovati (Foundation IRCCS Polyclinic San Matteo, Pavia)

100 / 1/2 de la 1/2 de la



"Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet". Vincent Ribrag (Gustave Roussy, Paris)



"ERN-EuroBloodNet Recommendations on Sickle Cell Disease." Béatrice Gulbis (H.U.B. Hôpital Erasme – ULB, Brussels)

THE STATE OF THE S



"EHA/ERN-EuroBloodNet Recommendations on Rare Hemolytic Anaemia" Richard van Wijk (University Medical Center Utrecht)



"Clinical practice guidelines on Vexas Syndrome endorsed by ERN-Eurobloodnet". Pierre Fenaux (AP-HP – Hôpital Saint Louis)



"Designing Patient-Centered Care: Patient Journeys from Educational Programs and Patient Versions of Guidelines.

Pilot of von Willebrand Disease and Burkitt Lymphoma". Mariangela Pellegrini (AP-HP – Hôpital Saint Louis)